Radhakrishnan, Ashwin
Pickup, Luke C.
Price, Anna M.
Law, Jonathan P.
McGee, Kirsty C.
Fabritz, Larissa
Senior, Roxy
Steeds, Richard P.
Ferro, Charles J.
Townend, Jonathan N.
Funding for this research was provided by:
University Hospitals Birmingham Charity
Metchley Park Medical Society
British Heart Foundation (FS/18/29/33554, FS/16/73/32314, FS/19/16/34169)
Article History
Received: 18 March 2021
Accepted: 19 April 2021
First Online: 26 April 2021
Declarations
:
: Patients included in this analysis were recruited from studies reviewed and approved by a National Health Service Research Ethics Committee [CRIB-FLOW study approved by the West Midlands—Solihull Research Ethics Committee (19/WM/0066), RETRACT study approved by the West Midlands—Black Country Research Ethics Committee (18/WM/0287)]. The studies were carried out in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consent.
: Not applicable.
: LF has received institutional research grants and non-financial support from the European Union, British Heart Foundation, Medical Research Council (UK), DFG and several biomedical companies. LF is listed as an inventor on two patents held by the University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). No other authors have any competing interests to declare.